Investigating Fractional Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap (ACO): A Scoping Review Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi Nafiseh Naderi Miriam Barrecheguren Abolfazl Dehghan Jean Bourbeau 10.6084/m9.figshare.7010363.v2 https://tandf.figshare.com/articles/dataset/Investigating_Fractional_Exhaled_Nitric_Oxide_in_Chronic_Obstructive_Pulmonary_Disease_COPD_and_Asthma-COPD_Overlap_ACO_A_Scoping_Review/7010363 <p>Chronic obstructive pulmonary disease (COPD) is the most common fixed airflow limitation. Individuals may present with the features of both asthma and COPD called asthma-COPD overlap (ACO) with more severity and worse health-related quality of life than COPD or asthma. One of the promising biomarkers that could be used in clinical practice to differentiate ACO from COPD is fractional exhaled nitric oxide (<i>F</i><sub>ENO</sub>). The role of Fractional exhaled nitric oxide (<i>F</i><sub>ENO</sub>) in COPD/ACO remains unknown. This scoping review aims to investigate the role of <i>F</i><sub>ENO</sub> measurement to differentiate COPD from ACO, to anticipate disease severity/progression and treatment response. A structured comprehensive literature search was performed in major databases including Medline, EMBASE, CINAHL, Cochrane Library, Web of Science, and BIOSIS from 2005 onwards. Thirty-eight studies were retrieved. Based on the synthesis of the reviewed literature, six themes emerged. Thirty-four articles covered more than one theme. From which, 24 articles were on modifying factors in <i>F</i><sub>ENO</sub> measurement, 18 on <i>F</i><sub>ENO</sub> in COPD compared with healthy subjects, and seven on <i>F</i><sub>ENO</sub> in ACO compared with COPD, 22 on <i>F</i><sub>ENO</sub> and disease severity/progression,12 on <i>F</i><sub>ENO</sub> and biomarkers, and eight on <i>F</i><sub>ENO</sub> and treatment response.</p> <p><i>F</i><sub>ENO</sub> measurement cannot be used alone in the clinical settings of COPD patients. Although <i>F</i><sub>ENO</sub> level is higher in ACO patients than COPD-only, it is still unclear if there is a <i>F</i><sub>ENO</sub> cut-off that can be used to make the diagnosis of ACO and/or to guide therapy with inhaled corticosteroids/glucocorticoids in COPD patients.</p> 2019-01-09 12:52:46 Fractional exhaled nitric oxide (FENO) chronic obstructive pulmonary disease (COPD) asthma-COPD overlap (ACO)